SCL Science Inc.

A246960

KR7246960009

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 23:00:00 26/05/2024 BST			5-day change	1st Jan Change
10,710 ^KRW	+3.98%		+5.52%	+20.74%

02-07	H2U Corp. announced that it has received KRW 1.29506497 billion in funding from InnoTherapy, Inc.	CI
2023	H2U Corp. announced that it has received KRW 1.2171 billion in funding from InnoTherapy, Inc.	CI

InnoTherapy, Inc. has filed an IPO.

June 21, 2017 at 05:00 am

InnoTherapy, Inc. has filed an IPO. Security Name: Shares Security Type: Common Stock PriceRange: KRW 17900 to KRW 23800

Latest news about SCL Science Inc.

H2U Corp. announced that it has received KRW 1.29506497 billion in funding from InnoTherapy, Inc.	02-06	CI
H2U Corp. announced that it has received KRW 1.2171 billion in funding from InnoTherapy, Inc.	11-29	CI
InnoTherapy, Inc. announced that it has received KRW 5.9999961 billion in funding from Scl Holdings and another investor	11-16	CI
Health to U Corporation announced that it has received funding from InnoTherapy, Inc.	11-08	CI
H2U Corp. announced that it expects to receive KRW 1.2171 billion in funding from InnoTherapy, Inc.	11-07	CI
InnoTherapy, Inc. announced that it expects to receive KRW 5.9999961 billion in funding	24/10/23	CI
PhAST Corp. announced that it has received KRW 1.30609774 billion in funding from InnoTherapy, Inc.	06/07/23	CI
Lee Moon Su completed the acquisition of a 98.04% stake in NVC 2019 Bio Health Care Investment Association from InnoTherapy, Inc.	29/06/23	CI
Lee Moon Su agreed to acquire 98.039216% stake in NVC 2019 Bio Health Care Investment Association from InnoTherapy, Inc. for approximately KRW5 billion.	25/06/23	CI
PhAST Corp. announced that it expects to receive KRW 1.30609774 billion in funding from InnoTherapy, Inc.	08/06/23	CI
InnoTherapy, Inc. announced that it has received KRW 4.999995 billion in funding from SCL Healthcare Co., Ltd., Seoul Clinical Laboratories	22/03/23	CI
InnoTherapy, Inc. announced that it expects to receive KRW 4.999995 billion in funding from SCL Healthcare Co., Ltd., Seoul Clinical Laboratories	12/03/23	CI
SCL Healthcare Co., Ltd. completed the acquisition of 22.97% stake in InnoTherapy, Inc. from Lee, Moon Soo.	27/12/22	CI
SCL Healthcare Co., Ltd. agreed to acquire 22.97% stake in InnoTherapy, Inc. from Lee, Moon Soo for KRW 21.8 billion.	17/11/22	CI
InnoTherapy, Inc. announced that it has received KRW 14.999868397 billion in funding from a group of investors	08/04/21	CI
InnoTherapy, Inc. announced that it expects to receive KRW 7.5 billion in funding from Samsung Securities Co. Ltd., Investment Arm, KB Securities Co., Ltd., Korea Investment & Securities Co., Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm, His-Story Investment Co.,Ltd., Shinhan Bank, Investment Arm, Shinhan Bank, Investment Arm, and Pureun Mutual Savings Bank Co., Ltd and another investor	31/03/21	CI
InnoTherapy, Inc. cancelled the acquisition of 98.04% stake in NVC 2019 Bio Health Care Investment Association.	14/10/20	CI
InnoTherapy, Inc. agreed to acquire 98.04% stake in NVC 2019 Bio Health Care Investment Association for KRW 5 billion.	14/10/19	CI
NVC Partners announced that it has received KRW 1.1 billion in funding from InnoTherapy, Inc.	30/06/19	CI
InnoTherapy, Inc. has completed an IPO in the amount of KRW 9 billion.	29/01/19	CI
InnoTherapy, Inc. has filed an IPO.	18/09/18	CI
InnoTherapy, Inc. has withdrawn its IPO.	17/09/18	CI
InnoTherapy, Inc. has filed an IPO.	21/06/17	CI

SCL Science Inc, formerly InnoTherapy Inc, is a Korea-based company principally engaged in the research, development, manufacture, export and sale of medical hemostatic agents. The main developed products include medical hemostats and sealants with biomimetic technology. In addition, the Company is engaged in the bio-logistics business.

Sector

Pharmaceuticals

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Biopharmaceuticals

	1st Jan change	Capi.
SCL SCIENCE INC.	+20.74%	57.3M
CSL LIMITED	-1.64%	90.28B
SAMSUNG BIOLOGICS CO.,LTD.	-0.66%	39.5B
BIOGEN INC.	-15.83%	31.71B
UCB	+61.66%	26.41B
BIOMARIN PHARMACEUTICAL INC.	-21.68%	14.34B
INCYTE CORPORATION	-8.73%	12.89B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-10.32%	11.8B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-45.77%	10.95B
SWEDISH ORPHAN BIOVITRUM AB	+3.60%	8.85B